<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2022-7.3.9</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-3553</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИНФЕКЦИОННЫЕ БОЛЕЗНИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INFECTIOUS DISEASES</subject></subj-group></article-categories><title-group><article-title>Анализ чувствительности к антибиотикам клинических изолятов коагулазонегативных стафилококков</article-title><trans-title-group xml:lang="en"><trans-title>Antibiotic sensitivity analysis of clinical coagulase-negative staphylococci</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5056-8177</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кононова</surname><given-names>Л. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kononova</surname><given-names>L. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ведущий инженер лаборатории биохимии развития  микроорганизмов</p><p>14081, г. Пермь, ул. Голева, 13, Россия</p></bio><bio xml:lang="en"><p> Leading Engineer at the Laboratory of Biochemistry of Microbial Development, Institute of Ecology and Genetics of Microorganisms</p><p> Goleva str. 13, Perm 614081, Russian Federation </p></bio><email xlink:type="simple">kononova_l@iegm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8473-771X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лемкина</surname><given-names>Л. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Lemkina</surname><given-names>L. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p> старший научный сотрудник лаборатории биохимии развития микроорганизмов</p><p>14081, г. Пермь, ул. Голева, 13, Россия</p></bio><bio xml:lang="en"><p> Senior Research Officer at the Laboratory of Biochemistry of Microbial Development, Institute of Ecology and Genetics of Microorganisms</p><p> Goleva str. 13, Perm 614081, Russian Federation </p></bio><email xlink:type="simple">l.lemkina@iegm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3475-8285</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коробов</surname><given-names>В. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Korobov</surname><given-names>V. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p> кандидат медицинских наук, доцент кафедры химии и биотехнологии; заведующий лабораторией биохимии развития микроорганизмов</p><p>14081, г. Пермь, ул. Голева, 13, Россия</p><p>614990, г. Пермь, Комсомольский просп., 29, Россия </p></bio><bio xml:lang="en"><p> Cand. Sc. (Med.), Associate Professor at the Department of Chemistry and Biotechnology; Head of the Laboratory of Biochemistry of the Development of Microorganisms, Institute of Ecology and Genetics of Microorganisms</p><p> Goleva str. 13, Perm 614081, Russian Federation </p><p> Komsomolsky ave. 29, Perm 614990, Russian Federation </p></bio><email xlink:type="simple">korobov@iegm.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Институт экологии и генетики микроорганизмов УрО РАН – филиал ФГБУН Пермского федерального исследовательского центра УрО РАН</institution></aff><aff xml:lang="en"><institution>Ural Branch Russian Academy of Sciences </institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Институт экологии и генетики микроорганизмов УрО РАН – филиал ФГБУН Пермского федерального исследовательского центра УрО РАН;&#13;
ФГАОУ ВО «Пермский национальный исследовательский политехнический университет»</institution></aff><aff xml:lang="en"><institution>Perm National Research Polytechnic University;&#13;
Ural Branch Russian Academy of Sciences </institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>05</day><month>07</month><year>2022</year></pub-date><volume>7</volume><issue>3</issue><fpage>75</fpage><lpage>89</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кононова Л.И., Лемкина Л.М., Коробов В.П., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Кононова Л.И., Лемкина Л.М., Коробов В.П.</copyright-holder><copyright-holder xml:lang="en">Kononova L.I., Lemkina L.M., Korobov V.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/3553">https://www.actabiomedica.ru/jour/article/view/3553</self-uri><abstract><sec><title> </title><p> </p></sec><sec><title>Введение</title><p>Введение. Возрастающая роль коагулазонегативных стафилококков в возникновении стафилококковых инфекций приводит к необходимости пристального внимания к ним. Требуется особенный контроль над чувствительностью бактерий к антибиотикам и распространением метициллинрезистентности как признака множественной устойчивости к антибактериальным препаратам. Важным является и выявление факторов вирулентности коагулазонегативных стафилококков, определяющих их поведение в среде обитания.Цель исследоваия. Оценить чувствительность штаммов коагулазонегативных стафилококков к клинически значимым антибиотикам даптомицину, ванкомицину, линезолиду и оксациллину и лантибиотику варнерину.Методы. Определение минимальных подавляющих рост клинических штаммов коагулазонегативных стафилококков концентраций антибактериальных соединений стандартными методами серийных разведений и дискодиффузионным методом. Выявление феномена сниженной чувствительности бактерий к ванкомицину популяционным анализом и градиентом концентраций. Липидный анализ методом тонкослойной хроматографии.Результаты. Показана высокая антибактериальная активность ванкомицина, даптомицина и линезолида в отношении клинических штаммов коагулазонегативных стафилококков. Выявлен верхний предел минимальных подавляющих концентраций ванкомицина в рамках чувствительного фенотипа и расширение диапазонов минимальных подавляющих концентраций даптомицина и варнерина в сторону увеличения оксациллинрезистентных изолятов. Установлен гетерогенный характер чувствительности к ванкомицину культур исследованных штаммов и возможность быстрого обогащения их субпопуляциями с пониженной чувствительностью к этому антибиотику. Селекция резистентности коагулазонегативных стафилококков к ванкомицину сопровождалась усилением синтеза лизилфосфатидилглицерина и снижением их чувствительности к катионным пептидным соединениям.Заключение. Обнаруженное преобладание метициллинрезистентного фенотипа клинических штаммов коагулазонегативных стафилококков, наряду с наличием в липидном спектре универсального фактора устойчивости к катионным антибактериальным соединениям, лизилфосфатидилглицерина, влечёт необходимость в новых методологических решениях диагностики инфекций, вызванных коагулазонегативными стафилококками.</p></sec></abstract><trans-abstract xml:lang="en"><p>Background. The increasing role of coagulase-negative staphylococci in the occurrence of staphylococcal infections leads to the need for close attention to them. Special control is required over the sensitivity of bacteria to antibiotics and the spread of methicillin resistance, as a sign of multiple resistance to antibacterial drugs. It is also important to identify the virulence factors of coagulase-negative staphylococci, which determine their behavior in the environment.The aim. To evaluate the sensitivity of strains of coagulase-negative staphylococci to clinically significant antibiotics daptomycin, vancomycin, linezolid and oxacillin and lantibiotic warnerin.Methods. Determination of the minimal inhibitory concentrations of antibacterial compounds for clinical coagulase-negative staphylococci by standard methods of serial dilutions and disc diffusion. Identification of the phenomenon of decreased susceptibility of bacteria to vancomycin by population analysis and concentration gradient. Lipid analysis by thin layer chromatography. Results. High antibacterial activity of vancomycin, daptomycin and linezolid against clinical strains of coagulase-negative staphylococci was shown. The upper limit of the minimum inhibitory concentrations of vancomycin within the sensitive phenotype and the expansion of the ranges of the minimum inhibitory concentrations of daptomycin and warnerin towards an increase in oxacillin-resistant isolates were revealed. The heterogeneous nature of sensitivity to vancomycin of the cultures of the studied strains and the possibility of their rapid enrichment with subpopulations with reduced sensitivity to this antibiotic have been established. The selection of resistance of coagulase-negative staphylococci to vancomycin was accompanied by an increase in the synthesis of lysylphosphatidylglycerol and a decrease in their sensitivity to cationic peptide compounds.Conclusion. The revealed prevalence of the methicillin-resistant phenotype of clinical strains of coagulase-negative staphylococci, along with the presence in the lipid spectrum of the universal factor of resistance to cationic antibacterial compounds, lysylphosphatidylglycerol, entails the need for new methodological solutions for diagnosing infections caused by coagulase-negative staphylococci.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гетерорезистентность</kwd><kwd>ванкомицин</kwd><kwd>варнерин</kwd><kwd>даптомицин</kwd><kwd>лантибиотики</kwd><kwd>лизилфосфатидилглицерин</kwd><kwd>линезолид</kwd><kwd>оксациллин</kwd><kwd>стафилококки</kwd><kwd>хоминин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>heteroresistance</kwd><kwd>vancomycin</kwd><kwd>warnerin</kwd><kwd>daptomycin</kwd><kwd>lantibiotics</kwd><kwd>lysylphosphatidylglycerol</kwd><kwd>linezolid</kwd><kwd>oxacillin</kwd><kwd>staphylococci</kwd><kwd>hominin</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках государственного задания «Молекулярные механизмы адаптации микроорганизмов к факторам среды», регистрационный номер НИОКТР АААА-А19-119112290009-1.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Дехнич А.В., Никулин А.А., Рябкова Е.Л., Кречикова О.И., Сухорукова М.В., Козлов Р.С. и др. Эпидемиология резистентности штаммов S. aureus, выделенных от пациентов в ОРИТ российских стационаров: результаты многоцентрового исследования. Клиническая микробиология и антимикробная химиотерапия. 2008; 10(4): 333-344.</mixed-citation><mixed-citation xml:lang="en">Dekhnich AV, Nikulin AA, Rjabkova EL, Krechikova OI, Suhorukova MV, Kozlov RS, et al. Epidemiology of antimicrobial resistance of S. aureus isolated from ICU patients in Russia: Results of prospective multicenter study. Clinical Microbiology and Antimicrobial Chemotherapy. 2008; 10(4): 333-344. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Романов А.В., Дехнич А.В., Сухорукова М.В., Склеенова Е.Ю., Иванчик Н.В., Эйдельштейн М.В. и др. Антибиотикорезистентность нозокомиальных штаммов Staphylococcus aureus в стационарах России: результаты многоцентрового эпидемиологического исследования «Марафон» в 2013–2014. Клиническая микробиология и антимикробная химиотерапия. 2017; 19(1): 57-62.</mixed-citation><mixed-citation xml:lang="en">Romanov АV, Dekhnich АV, Sukhorukova МV, Skleenova ЕYu, Ivanchik NV, Edelstein МV, et al. Antimicrobial resistance of nosocomial Staphylococcus aureus isolates in Russia: Results of multicenter epidemiological study «MARATHON» 2013-2014. Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(1): 57-62. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Зайцев А.А., Карпов О.И., Сидоренко С.В. Стафилококки и ванкомицин: тенденции противостояния. Антибиотики и химиотерапия. 2003; 48(6): 20-26.</mixed-citation><mixed-citation xml:lang="en">Zaitsev AA, Karpov OI, Sidorenko SV. Staphylococci and vancomycin: Trends in confrontation. Antibiotics and Chemotherapy. 2003; 48(6): 20-26. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997; 350(9092): 1670-1673. doi: 10.1016/S0140-6736(97)07324-8</mixed-citation><mixed-citation xml:lang="en">Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997; 350(9092): 1670-1673. doi: 10.1016/S0140-6736(97)07324-8</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Center KJ, Reboli AC, Hubler R, Rodgers GL, Long SS. Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: Evidence of spread of Staphylococcus warneri. J Clin Microbiol. 2003; 41(10): 4660-4665. doi: 10.1128/JCM.41.10.4660-4665.2003</mixed-citation><mixed-citation xml:lang="en">Center KJ, Reboli AC, Hubler R, Rodgers GL, Long SS. Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of Staphylococcus warneri. J Clin Microbiol. 2003; 41(10): 4660-4665. doi: 10.1128/JCM.41.10.4660-4665.2003</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Cremniter J, Slassi A, Quincampoix JC, Sivadon-Tardy V, Bauer T, Porcher R, et al. Decreased susceptibility to teicoplanin and vancomycin in coagulase-negative staphylococci isolated from orthopedic-device-associated infections. J Clin Microbiol. 2010; 48(4): 1428-14231. doi: 10.1128/JCM.02098-09</mixed-citation><mixed-citation xml:lang="en">Cremniter J, Slassi A, Quincampoix JC, Sivadon-Tardy V, Bauer T, Porcher R, et al. Decreased susceptibility to teicoplanin and vancomycin in coagulase-negative staphylococci isolated from orthopedic-device-associated infections. J Clin Microbiol. 2010; 48(4): 1428-14231. doi: 10.1128/JCM.02098-09</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Jones T, Yeaman MR, Sakoulas G, Yang SJ, Proctor RA, Sahl HG, et al. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother. 2008; 52(1): 269-278. doi: 10.1128/AAC.00719-07</mixed-citation><mixed-citation xml:lang="en">Jones T, Yeaman MR, Sakoulas G, Yang SJ, Proctor RA, Sahl HG, et al. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother. 2008; 52(1): 269-278. doi: 10.1128/AAC.00719-07</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Oku Y, Kurokawa K, Ichihashi N, Sekimizu K. Characterization of the Staphylococcus aureus mprF gene, involved in lysinylation of phosphatidylglycerol. Microbiology (Reading). 2004; 150(1): 45-51. doi: 10.1099/mic.0.26706-0</mixed-citation><mixed-citation xml:lang="en">Oku Y, Kurokawa K, Ichihashi N, Sekimizu K. Characterization of the Staphylococcus aureus mprF gene, involved in lysinylation of phosphatidylglycerol. Microbiology (Reading). 2004; 150(1): 45-51. doi: 10.1099/mic.0.26706-0</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization, Antimicrobial Resistance Division. 2020 antibacterial agents in clinical and preclinical development: An overview and analysis. Geneva, Switzerland; 2021. URL: https://www.who.int/publications/i/item/9789240021303 [date of access: 11.05.2022].</mixed-citation><mixed-citation xml:lang="en">World Health Organization, Antimicrobial Resistance Division. 2020 antibacterial agents in clinical and preclinical development: An overview and analysis. Geneva, Switzerland; 2021. URL: https://www.who.int/publications/i/item/9789240021303 [date of access: 11.05.2022].</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Сабирова Е.В., Гординская Н.А., Абрамова Н.В., Некаева Е.С. Антибиотикорезистентность нозокомиальных штаммов Staphylococcus spp., выделенных в ожоговом центре в 2002–2008 гг. Клиническая микробиология и антимикробная химиотерапия. 2010; 12(1): 77-81.</mixed-citation><mixed-citation xml:lang="en">Sabirova EV, Gordinskaya NA, Abramova NV, Nekaeva ES. Antimicrobial resistance of nosocomial staphylococci isolated from burn center patients in 2002-2008. Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12(1): 77-81. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. Clin Microbiol Rev. 2014; 27(4): 870-926. doi: 10.1128/CMR.00109-13</mixed-citation><mixed-citation xml:lang="en">Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. Clin Microbiol Rev. 2014; 27(4): 870-926. doi: 10.1128/CMR.00109-13</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Clinical and laboratory standards institute (CLSI). Performance standards for antimicrobial susceptibility testing; twentyfourth informational supplement. 2014: 34(1).</mixed-citation><mixed-citation xml:lang="en">Clinical and laboratory standards institute (CLSI). Performance standards for antimicrobial susceptibility testing; twentyfourth informational supplement. 2014: 34(1).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Полюдова Т.В., Лемкина Л.М., Лихацкая Г.Н., Коробов В.П. Оптимизация условий получения и моделирование 3D-структуры нового антибактериального пептида семейства лантибиотиков. Прикладная биохимия и микробиология. 2017; 53(1): 47-54. doi: 10.7868/S0555109917010147</mixed-citation><mixed-citation xml:lang="en">Polyudova TV, Lemkina LM, Korobov VP, Likhatskaya GN. Optimization of production conditions and 3D-structure modeling of novel antibacterial peptide of lantibiotic family. Prikladnaya biokhimiya i mikrobiologiya. 2017; 53(1): 40-46. (In Russ.). doi: 10.1134/S0003683817010148</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Кононова Л.И., Коробов В.П. Физиологические особенности устойчивого к ванкомицину штамма Staphylococcus epidermidis 33 GISK VAN R. Микробиология. 2015; 84(1): 58-67. doi: 10.7868/S0026365615010061</mixed-citation><mixed-citation xml:lang="en">Kononova LI, Korobov VP. Physiological properties of the vancomycin-resistant strain Staphylococcus epidermidis 33 GISK VANR. Microbiology (Mikrobiologiya). 2015; 84(1): 41-48. (In Russ.). doi: 10.7868/S0026365615010061</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Коробов В.П., Лемкина Л.М., Полюдова Т.В., Акименко В.К. Выделение и характеристика нового низкомолекулярного антибактериального пептида семейства лантибиотиков. Микробиология. 2010; 79(2): 228-238.</mixed-citation><mixed-citation xml:lang="en">Korobov VP, Lemkina LM, Polyudova TV, Akimenko VK. Isolation and characterization of a new low-molecular antibacterial peptide of the lantibiotics family. Microbiology (Mikrobiologiya). 2010; 79(2): 206-215. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Коробов В.П., Лемкина Л.М., Полюдова Т.В. Антибактериальный пептид хоминин KLP-1 широкого спектра действия: Патент № 2528055 Рос. Федерация; МПК C07K 14/31 (2006.01), A61K 38/16 (2006.01), C12R 1/44 (2006.01); заявитель и патентообладатель Федеральное государственное бюджетное учреждение науки Институт экологии и генетики микроорганизмов Уральского отделения Российской академии наук. № 2012125512/10; заявл. 19.06.2012; опубл. 10.09.2014. 2014; (25).</mixed-citation><mixed-citation xml:lang="en">Korobov VP, Lemkina LM, Polyudova TV. Broad spectrum antibacterial peptide hominin KLP-1: Patent N 2528055 of the Russian Federation. 2014; (25). (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Clinical and laboratory standards institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard; 9th edition. 2012: 32(2).</mixed-citation><mixed-citation xml:lang="en">Clinical and laboratory standards institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard; 9th edition. 2012: 32(2).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother. 2001; 47(4): 399-403. doi: 10.1093/jac/47.4.399</mixed-citation><mixed-citation xml:lang="en">Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother. 2001; 47(4): 399-403. doi: 10.1093/jac/47.4.399</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Hanaki H, Hiramatsu K. Detection methods of glycopeptideresistant Staphylococcus aureus I: Susceptibility testing. Antibiotic Resistance. Methods in Molecular Medicine™. Ed. SH Gillespie. Humana Press; 2001; 48: 85-92. doi: 10.1385/1-59259-077-2:85</mixed-citation><mixed-citation xml:lang="en">Hanaki H, Hiramatsu K. Detection methods of glycopeptideresistant Staphylococcus aureus I: Susceptibility testing. Antibiotic Resistance. Methods in Molecular Medicine™. Ed. SH Gillespie. Humana Press; 2001; 48: 85-92. doi: 10.1385/1-59259-077-2:85</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillinresistant Staphylococcus aureus infection. New Engl J Med. 1999; 340(7): 517-523. doi: 10.1056/NEJM199902183400704</mixed-citation><mixed-citation xml:lang="en">Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillinresistant Staphylococcus aureus infection. New Engl J Med. 1999; 340(7): 517-523. doi: 10.1056/NEJM199902183400704</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37(8): 911-917. doi: 10.1139/o59-099</mixed-citation><mixed-citation xml:lang="en">Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37(8): 911-917. doi: 10.1139/o59-099</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Fewster ME, Burns BJ, Mead JF. Quantitative densitometric thin-layer chromatography of lipids using copper acetate reagent. J Chromatogr. 1969; 43(1): 120-126. doi: 10.1016/s0021-9673(00)99173-8</mixed-citation><mixed-citation xml:lang="en">Fewster ME, Burns BJ, Mead JF. Quantitative densitometric thin-layer chromatography of lipids using copper acetate reagent. J Chromatogr. 1969; 43(1): 120-126. doi: 10.1016/s0021-9673(00)99173-8</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Кейтс M. Техника липидологии. Выделение, анализ и идентификация липидов. М.: Мир; 1975.</mixed-citation><mixed-citation xml:lang="en">Kates M. Techniques of lipidology. Isolation, analysis and identification of lipids. Moscow: Mir Piblishing House; 1975. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Граничная Н.В., Зайцева Е.А., Переломова О.В. Резистентность коагулазонегативных стафилококков, выделенных из различного биоматериала у пациентов кардиохирургического профиля. Тихоокеанский медицинский журнал. 2019; 2(76): 38-42. doi: 10.17238/PmJ1609-1175.2019.2.28-42</mixed-citation><mixed-citation xml:lang="en">Granichnaya NV, Zaytseva EA, Perelomova OV. Resistance of coagulase negative staphylococci recovered from different biomaterials in cardiac patients. Pacific Medical Journal. 2019; 2(76): 38-42. (In Russ.). doi: 10.17238/PmJ1609-1175.2019.2.28-42</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kelley PG, Gao W, Ward PB, Howden BP. Daptomycin nonsusceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): Implications for therapy after vancomycin treatment failure. J Antimicrob Chemother. 2011; 66(5): 1057-1060. doi: 10.1093/jac/dkr066</mixed-citation><mixed-citation xml:lang="en">Kelley PG, Gao W, Ward PB, Howden BP. Daptomycin nonsusceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): Implications for therapy after vancomycin treatment failure. J Antimicrob Chemother. 2011; 66(5): 1057-1060. doi: 10.1093/jac/dkr066</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Howden BP, Johnson PDR, Ward PB, Stinear TP, Davies JK. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006; 50(9): 3039-3047. doi: 10.1128/AAC.00422-06</mixed-citation><mixed-citation xml:lang="en">Howden BP, Johnson PDR, Ward PB, Stinear TP, Davies JK. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006; 50(9): 3039-3047. doi: 10.1128/AAC.00422-06</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Pinheiro L, Brito CI, Pereira VC, de Oliveira A, Camargo CH, Cunha M de L. Reduced susceptibility to vancomycin and biofilm formation in methicillin-resistant Staphylococcus epidermidis isolated from blood cultures. Mem Inst Oswaldo Cruz. 2014; 109(7): 871-878. doi: 10.1590/0074-0276140120</mixed-citation><mixed-citation xml:lang="en">Pinheiro L, Brito CI, Pereira VC, de Oliveira A, Camargo CH, Cunha M de L. Reduced susceptibility to vancomycin and biofilm formation in methicillin-resistant Staphylococcus epidermidis isolated from blood cultures. Mem Inst Oswaldo Cruz. 2014; 109(7): 871-878. doi: 10.1590/0074-0276140120</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Barber KE, Werth BJ, Ireland CE, Stone NE, Nonejuie P, Sakoulas G, et al. Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes. J Antimicrob Chemother. 2014; 69(11): 3006-3010. doi: 10.1093/jac/dku236</mixed-citation><mixed-citation xml:lang="en">Barber KE, Werth BJ, Ireland CE, Stone NE, Nonejuie P, Sakoulas G, et al. Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes. J Antimicrob Chemother. 2014; 69(11): 3006-3010. doi: 10.1093/jac/dku236</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Chopra L, Singh G, Taggar R, Dwivedi A, Nandal J, Kumar P, et al. Antimicrobial peptides from bacterial origin: Potential alternative to conventional antibiotics. High Value Fermentation Products; ed. by S. Saran, V. Babu, A. Chuabey. Scrivener; 2019: 193-204. doi: 10.1002/9781119460053.ch8</mixed-citation><mixed-citation xml:lang="en">Chopra L, Singh G, Taggar R, Dwivedi A, Nandal J, Kumar P, et al. Antimicrobial peptides from bacterial origin: Potential alternative to conventional antibiotics. High Value Fermentation Products; ed. by S. Saran, V. Babu, A. Chuabey. Scrivener; 2019: 193-204. doi: 10.1002/9781119460053.ch8</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Werth BJ, Vidaillac C, Murray KP, Newton KL, Sakoulas G, Nonejuie P, et al. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA. Antimicrob Agents Chemother. 2013; 57(5): 2376-2379. doi: 10.1128/AAC.02354-12</mixed-citation><mixed-citation xml:lang="en">Werth BJ, Vidaillac C, Murray KP, Newton KL, Sakoulas G, Nonejuie P, et al. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA. Antimicrob Agents Chemother. 2013; 57(5): 2376-2379. doi: 10.1128/AAC.02354-12</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Mun S-H, Kang O-H, Joung D-K, Kim S-B, Choi J-G, Shin D-W, et al. In vitro anti-MRSA activity of carvone with gentamicin. Exp Ther Med. 2014; 7(4): 891-896. doi: 10.3892/etm.2014.1498</mixed-citation><mixed-citation xml:lang="en">Mun S-H, Kang O-H, Joung D-K, Kim S-B, Choi J-G, Shin D-W, et al. In vitro anti-MRSA activity of carvone with gentamicin. Exp Ther Med. 2014; 7(4): 891-896. doi: 10.3892/etm.2014.1498</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Ernst CM, Peschel A. Broad-spectrum antimicrobial peptide resistance by MprF-mediated aminoacylation and flipping of phospholipids. Mol Microbiol. 2011; 80(2): 290-299. doi: 10.1111/j.1365-2958.2011.07576.x</mixed-citation><mixed-citation xml:lang="en">Ernst CM, Peschel A. Broad-spectrum antimicrobial peptide resistance by MprF-mediated aminoacylation and flipping of phospholipids. Mol Microbiol. 2011; 80(2): 290-299. doi: 10.1111/j.1365-2958.2011.07576.x</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Geiger O, González-Silva N, López-Lara IM, Sohlenkamp C. Amino acid-containing membrane lipids in bacteria. Prog Lipid Res. 2010; 49(1): 46-60. doi: 10.1016/j.plipres.2009.08.002</mixed-citation><mixed-citation xml:lang="en">Geiger O, González-Silva N, López-Lara IM, Sohlenkamp C. Amino acid-containing membrane lipids in bacteria. Prog Lipid Res. 2010; 49(1): 46-60. doi: 10.1016/j.plipres.2009.08.002</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Peschel A, Jack RW, Otto M, Collins LV, Staubitz P, Nicholson G, et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med. 2001; 193(9): 1067-1076. doi: 10.1084/jem.193.9.1067</mixed-citation><mixed-citation xml:lang="en">Peschel A, Jack RW, Otto M, Collins LV, Staubitz P, Nicholson G, et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med. 2001; 193(9): 1067-1076. doi: 10.1084/jem.193.9.1067</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Satola SW, Farley MM, Anderson KF, Patel JB. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol. 2011; 49(1): 177-183. doi: 10.1128/JCM.01128-10</mixed-citation><mixed-citation xml:lang="en">Satola SW, Farley MM, Anderson KF, Patel JB. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol. 2011; 49(1): 177-183. doi: 10.1128/JCM.01128-10</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Sieradzki K, Villari P, Tomasz A. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother. 1998; 42(1): 100-107. doi: 10.1128/AAC.42.1.100</mixed-citation><mixed-citation xml:lang="en">Sieradzki K, Villari P, Tomasz A. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother. 1998; 42(1): 100-107. doi: 10.1128/AAC.42.1.100</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol. 2001; 39(7): 2439-2444. doi: 10.1128/JCM.39.7.2439-2444.2001</mixed-citation><mixed-citation xml:lang="en">Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol. 2001; 39(7): 2439-2444. doi: 10.1128/JCM.39.7.2439-2444.2001</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Lulitanond A, Chanawong A, Sribenjalux P, Kaewkes W, Vorachit M, Chongtrakool P, et al. Detection of heterogeneous, intermediate-vancomycin-resistant Staphylococcus aureus (hVISA) using low-concentration vancomycin disks. Southeast Asian J Trop Med Public Health. 2006; 37(4): 761-767.</mixed-citation><mixed-citation xml:lang="en">Lulitanond A, Chanawong A, Sribenjalux P, Kaewkes W, Vorachit M, Chongtrakool P, et al. Detection of heterogeneous, intermediate-vancomycin-resistant Staphylococcus aureus (hVISA) using low-concentration vancomycin disks. Southeast Asian J Trop Med Public Health. 2006; 37(4): 761-767.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Cafiso V, Bertuccio T, Spina D, Purrello S, Campanile F, Di Pietro C, et al. Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains. PLoS One. 2012; 7(1): e29573. doi: 10.1371/journal.pone.0029573</mixed-citation><mixed-citation xml:lang="en">Cafiso V, Bertuccio T, Spina D, Purrello S, Campanile F, Di Pietro C, et al. Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains. PLoS One. 2012; 7(1): e29573. doi: 10.1371/journal.pone.0029573</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
